The Mount Sinai Health System is home to dozens of research institutes, centers, and laboratories, and the trailblazing research projects we conduct are translated into real-world health care products and services
Devices
- The surgical reshaping of a heart valve is called an annuloplasty procedure. In some surgeries, an annuloplasty ring, made of plastic, metal and fabric, may be implanted to maintain the shape of the heart valve.
- Inventor: David Adams
- Licensee: Medtronic and Edwards Lifesciences
- Pipeline Status: Marketed
- Learn More
- Joint replacement technology is mostly the same today as it was 40 years ago. Surgeons use instruments such as hand saws and jigs to prepare the bone for rigid, generic implants. Monogram is developing implants that can be patient optimized and designed to meet an individual patient’s anatomy as precisely as possible.
- Inventor: Douglas Unis
- Licensee: Monogram
- Pipeline Status: Prototype
- Dermatologists have long used ultraviolet light to treat skin disorders such as psoriasis and vitiligo. Unlike older UV therapies, the excimer laser technology uses a highly targeted beam of therapeutic UVB light to treat affected skin areas without damaging surrounding healthy skin.
- Inventor: James Spencer
- Licensee: N/A
- Pipeline Status: Marketed
Diagnostic
Mount Sinai Health System and Renalytix AI together formed Kantaro Biosciences, a Mount Sinai venture, to develop and scale production and distribution of a test kit based on the Mount Sinai-developed high-performance serologic assay for SARS-CoV-2 antibodies.
-
- Inventor: Florian Krammer
- Licensee: Kantaro
- Pipeline Status: Marketed
- The StrandDx™-ASD diagnostic aid uses novel molecular biomarkers to assess the likelihood of ASD in children from birth to 18 months old, and to aid in diagnosis of ASD in patients aged 18 months to 21 years. The test is based on technology developed at the Icahn School of Medicine at Mount Sinai.
- Inventor: Manish Arora
- Licensee: Linus Biotechnology
- Pipeline: In Development
- FractalDx kidney transplant diagnostic portfolio research programs demonstrate that a blood test can diagnose kidney rejection before clinical signs of kidney damage, improving the therapeutic management and long-term viability of a transplanted kidney.
- Inventor: Barbara Murphy
- Licensee: Renalytix
- Pipeline Status: Marketed
- Mount Sinai’s Lab100 is a clinic and research lab that combines advanced medical diagnostic screening tools, digital applications, and data science to provide patients comprehensive health reports and give scientists a more sophisticated understanding of the biomarkers, behavior patterns, and other keys to preventing disease.
- Inventor: David Stark
- Licensee: Onegevity
- Pipeline Status: In Development
- More than 30 million people in the United States and Europe have food allergies. The epitope mapping platform developed at the Icahn School of Medicine at Mount Sinai provides an improved method for detecting, assessing, and monitoring food allergies in patients.
- Inventors: Hugh Sampson, Rosalia Ayuso, Bob Getts
- Licensee: AllerGenis
- Pipeline Status: Marketed
- PreciseDx has the first lab dedicated to leveraging AI to better inform pathology. Its objective is to receive digital scans and glass slides from pathologists, oncologists, and other specialists, and quickly produce and deliver reports with AI-powered insights in a timely manner.
- Inventor: Carlos Cordon-Cardo
- Licensee: PreciseDx
- Pipeline Status: Marketed
- Spinal muscular atrophy (SMA) is a group of hereditary diseases that progressively destroy motor neurons, leading to muscle weakness and atrophy. Screening for SMA allows the opportunity for earlier, more effective, treatment.
- Inventor: Lisa Edelmann
- Licensee: N/A
- Pipeline Status: Marketed
- The VerifyNow system is a platform and suite of tests for the assessment of platelet reactivity to all major antiplatelet therapies such as aspirin, clopidogrel, prasugrel, and GP IIb/IIIa inhibitors. It provides an accurate way to guide treatment decisions in patients who may be at risk of a life-threatening thrombotic event or bleeding complication.
- Inventor: Barry Coller
- Licensee: Accumetrics
- Pipeline Status: Marketed
Research Tools
- The Personal Discovery Process (PDP), developed by the Icahn School of Medicine at Mount Sinai, is effectively a massive clinical trial for a single patient. Mutations comprising a patient’s tumor network are engineered into an army of 500,000 fruit fly “avatars,” and then up to 2,000 FDA/NICE approved drugs are evaluated via these avatars to identify effective drug combinations.
- Inventor: Ross Cagan
- Licensee: My Personal Therapeutics
- Pipeline Status: Preclinical
Software
- The GRITT-IBD program is designed to help patients build strengths that give them the resilience to recover from difficulties associated with inflammatory bowel disease (IBD). GRITT stands for Gaining Resilience Through Transitions and utilizes multidisciplinary care management in person and via telehealth.
- Inventors: Laurie Keefer, Marla Dubinsky
- Licensee: Trellus Health
- Pipeline Status: Marketed
- KidneyIntelX is a test that yields a simple-to-understand risk score, predicting which adult patients with type 2 diabetes and with chronic kidney disease stages 1-3b are at low, intermediate, or high risk for rapid progressive decline in kidney function.
- Inventors: Girish Nadkarni, Steven Coca
- Licensee: Renalytix
- Pipeline Status: Marketed
Therapeutics
- Bryostatins are a family of protein kinase C modulators that have potential applications in biomedicine. Studies conducted at the Icahn School of Medicine at Mount Sinai demonstrated the effectiveness of bryostatin in improving lipid transport in Niemann-Pick Type C1 cells.
- Inventor: Yiannis Ioannou
- Licensee: Neurotrope
- Pipeline Status: Preclinical
-
- Fabry disease is a genetic condition that results in reduced activity of an enzyme in the body called alpha-galactosidase A (alpha-Gal A). Fabrazyme is an enzyme replacement therapy (ERT) that supplies the enzyme that’s missing or deficient in Fabry disease.
- Inventor: Robert Desnik
- Licensee: Genzyme
- Pipeline Status: Marketed
- Fabry disease is a genetic condition that results in reduced activity of an enzyme in the body called alpha-galactosidase A (alpha-Gal A). Fabrazyme is an enzyme replacement therapy (ERT) that supplies the enzyme that’s missing or deficient in Fabry disease.
- Inventor: Jian-Qiang (Jim) Fan
- Licensee: Amicus
- Pipeline Status: Marketed
- Acute Hepatic Porphyria (AHP) is a family of rare, genetic diseases that can cause severe and potentially life-threatening attacks. In people with AHP, the production of heme–a precursor to hemoglobin–does not happen properly because of a genetic mutation. This causes certain toxins to build up in the liver and be released throughout the body. GIVLAARI ® reduces the amount of ALAS1 in the liver, which reduces levels of these toxins.
- Inventor: Robert Desnick
- Licensee: Alnylam
- Pipeline Status: Marketed
- Cullinan Oncology and the Icahn School of Medicine at Mount Sinai have entered into a collaboration agreement to develop novel small molecule immune modulators. The goal is to accelerate the development of best-in-class HPK1 degraders that stimulate robust anti-tumor immunity.
- Inventors: Jian Jin, Steven J. Burakoff
- Licensee: Cullinan Oncology
- Pipeline Status: Preclinical
- Mucopolysaccharidosis (MPS) is a group of 11 metabolic disorders caused by genetic defects that affect the skeletal system, skin, heart, brain, and other organ systems and can lead to disability or death. Mount Sinai innovators are working with Paradigm Biopharmaceuticals and ReqMed to advance injectable pentosan polysulfate sodium (iPPS) for the treatment of MPS.
- Inventors: Calogera Simonaro, Edward Schuchman
- Licensee: ReqMed, Paradigm Biopharma
- Pipeline Status: Preclinical, Phase 2
-
- The sarcoidosis program at Mount Sinai, led by Adam Morgenthau, MD, is exploring the biology of the disease to increase our understanding of how the condition develops and advances. The studies include a clinical trial to evaluate the safety and efficacy of treating sarcoidosis with KIACTA™.
- Inventor: Adam Morgenthau
- Licensee: Auven Therapeutics
- Pipeline Status: Marketed
-
-
- MicroRNAs (miRNAs) are short, non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms. miR-128 is a miRNA that modulates vascular smooth muscle cells, a role that could be used for therapeutic purposes.
- Inventor: Anne Schaefer
- Licensee: Regenxbio
- Pipeline Status: Preclinical
-
- Molecular glues are protein-binding small molecules that can change interactions between proteins and cellular networks and are a potential treatment for human cancer and neurodegenerative diseases.
- Inventor: Arvin Dar
- Licensee: Nested Therapeutics
- Pipeline Status: Preclinical
- Monoclonal antibodies are a class of drugs that can disrupt disease pathology by blocking receptors or interfering with cell-to-cell transmission.
- Inventors: Domenico Tortorella, James Duty, Robert Allen
- Licensee: Sorrento Therapeutics
- Pipeline Status: Phase 1
-
- A new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it eliminate tumor cells using nanobiologics, tiny materials bioengineered from natural molecules that are paired with a therapeutic component.
- Inventors: Jordi Orchando, Willem Mulder
- Licensee: Trained Therapeutics
- Pipeline Status: Preclinical
- Influenza is a contagious disease that spreads around the United States every year, usually between October and May. Nasal Flu Vaccine is a vaccine that is sprayed into the nose to help protect against influenza.
- Inventors: Peter Palese, Adolfo Garcia-Sastre
- Licensee: N/A
- Pipeline Status: Marketed
- Newcastle disease virus (NDV) vaccines in animal models suggests that an NDV-based vaccine, which can be produced from embryonated chicken eggs, would be a safe and highly scalable way to meet the vast demands of the global vaccine market.
- Inventors: Adolfo Garcia-Sastre, Florian Krammer, Peter Palese
- Licensee: Avi-Mex, CastleVaxs
- Pipleline Status: Phase 2
- Niemann-Pick disease is a group of diseases passed down through families in which fatty substances called lipids collect in the cells of the spleen, liver, and brain. Olipudase alfa is an investigational enzyme replacement therapy for treatment of Type B Niemann-Pick disease.
- Inventors: Edward Schuchman, Scott Friedman
- Licensee: Sanofi (Genz)
- Pipeline Status: Marketed
- Endometriosis is a condition where the tissue that forms in the lining of the uterus continues to grow outside the uterus. ORILISSA®, a drug that resulted from research conducted at Mount Sinai, helps to ease the moderate to severe pain that accompanies this condition.
- Inventor: Stuart C Sealfon
- Licensee: Neurocrine Biosciences
- Pipeline Status: Marketed
- PERK is a transmembrane serine/threonine protein kinase that appears to have both pro- and anti-tumorigenic properties. PERK inhibitors (PERKi) are being tested for anti-tumor activity.
- Inventor: Julio Aguirre Guiso
- Licensee: HiberCell
- Pipeline Status: Phase 1
- Newcastle disease and avian influenza are two dreaded diseases in the poultry population. Mount Sinai inventors added the H5 gene to the Newcastle vaccine. When chickens were exposed to avian influenza and the Newcastle disease virus, birds vaccinated with the recombinant vaccine produced protection against both viruses.
- Inventors: Peter Palese, Adolfo Garcia-Sastre
- Licensee: Avi-Mex
- Pipeline Status: Marketed
- Fabry disease is a genetic condition that results in reduced activity of an enzyme in the body called alpha-galactosidase A (alpha-Gal A). Replagal is a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease.
- Inventor: Robert Desnick
- Licensee: Shire
- Pipeline Status: Marketed
- ACG-801 (formerly known as RVT-801) is an investigational form of recombinant human acid ceramidase (rhAC) designed to address the genetic deficiency of the naturally occurring enzyme that causes Farber disease. Data in animal models also supports the potential of rhAC as a treatment for cystic fibrosis.
- Inventor: Edward Schuchman
- Licensee: Aceragen
- Pipeline Status:Preclinical
- RUC-4 is a next-generation investigational GPIIb/IIIa platelet inhibitor for rapid pre-hospital treatment of STEMI heart attacks, the most severe form of heart attack, where blood flow to a portion of the heart is almost always cut off by a blood clot.
- Inventor: Marta Filizola
- Licensee: Celecor
- Pipeline Status: Preclinical
- Farber disease is a lysosomal storage disease with a unique, severe inflammatory phenotype for which no disease-specific therapy exists. RVT-801 is an investigational enzyme replacement therapy designed to address the genetic deficiency of the naturally occurring enzyme that causes Farber disease.
- Inventor: Edward Schuchman
- Licensee: Aceragen
- Pipeline Status: Preclinical
- Click Therapeutics develops software as prescription medical treatments and, with CT-152, is researching multiple cognitive exercises for the treatment of Major Depressive Disorder.
- Inventor: Brian Iacoviello, Dennis Charney
- Licensee: Click Therapeutics
- Pipeline Status: Phase 3
- Icahn Mount Sinai Dean Dennis Charney, MD, co-invented a patented method of treating patients with treatment-resistant depression which was part of the drug application for Janssen’s SPRAVATO ® (esketamine) CIII nasal spray.
- Inventor: Dean Charney
- Licensee: Janssen
- Pipeline Status: Marketed
- TRAP1 is a protein that helps mitochondria work properly. Data from studies at the Icahn School of Medicine at Mount Sinai demonstrates that TRAP1 is a potential novel therapeutic target for multiple disorders that affect the central nervous system.
- Inventor: Yiannis Ioannou
- Licensee: Amathus Therapeutics
- Pipeline Status: Preclinical
- WDR5 is a protein that plays an important role in driving the proliferation of cancers such as acute myeloid leukemia and pancreatic cancer. Researchers believe that it is likely that WDR5 small-molecule degraders, which eliminate this protein, could be effective in treating these cancers.
- Inventors: Jian Jin, Steven J. Burakoff
- Licensee: Cullgen
- Pipeline Status: Preclinical